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OBJECTIVES This investigation sought to determine the effect of phentermine-fenfluramine (phen-fen) on
the prevalence of valvular heart disease in 226 obese subjects enrolled in a prospective, strict
weight loss, research protocol.
BACKGROUND Early reports have suggested that the use of phen-fen for weight loss may be associated with
increased valvular heart disease. Such reports were based on small numbers of patients, limited
data on dose and duration of phen-fen therapy, and no correlation with matched controls.
METHODS All subjects underwent transthoracic echocardiography for significant valvular lesions within
a mean of 97 days from the manufacturer’s announcement of the voluntary withdrawal of
fenfluramine and dexfenfluramine. All echocardiograms were interpreted by two independent
readers.
RESULTS The study population included 183 women and 43 men with a mean age of 46.9 6 8.9 years
and mean starting body mass index of 39.8 6 7.7 kg/m2. Using the Food and Drug
Administration criteria, significant aortic regurgitation was detected in 15 subjects (6.6%) and
mitral regurgitation in 3 subjects (1.3%). Only one patient had significant regurgitation of
both aortic and mitral valves. No valves had severe regurgitation. Significant valvular disease
did not correlate with the dose or duration of phen-fen therapy. Furthermore, the prevalence
of valvular regurgitation is comparable to the normal offspring in the Framingham Heart
Study, who are similar in age, gender, and geographical location.
CONCLUSIONS Phen-fen therapy is associated with a low prevalence of significant valvular regurgitation.
Valvular regurgitation in our subjects may reflect age-related degenerative changes. (J Am
Coll Cardiol 1999;34:1153–8) © 1999 by the American College of Cardiology
Phentermine and fenfluramine (phen-fen) are medications
that are prescribed as anorectic agents for the treatment of
obesity. In 1996, the total number of prescriptions for these
drugs exceeded 18 million (1), even though the Food and
Drug Administration (FDA) has never approved their
combination use. In August 1997, researchers at the Mayo
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Clinic reported on 24 women with echocardiographic evi-
dence of unusual valvular pathology and regurgitation in-
volving both right- and left-sided heart valves (2). Follow-
ing the Mayo Clinic report, numerous anecdotal reports and
several small, nonrandomized observational surveys have
described significant, unsuspected cardiac pathology in pa-
tients formerly on phen-fen with reported prevalence of
valvular disease up to 38% (3).
The pathologic valvular changes in patients on phen-fen
are felt to resemble those seen in patients with carcinoid
syndrome and ergot-alkaloid–induced valvular heart disease:
fibroplasia involving the valvular endocardium of both
right- and left-sided valves (2,4–6). These changes resem-
ble chronic rheumatic valve disease, but without evidence of
valvular stenosis. Subvalvular involvement, including
chordal thickening and retraction, has been noted with
variable degrees of valvular regurgitation (5). To what extent
these changes are fixed or reversible is not yet known,
because no long-term prospective trials have been per-
formed.
We now report the echocardiographic findings in a
cohort of 226 subjects who received phen-fen for treatment
of obesity and who were followed prospectively over the
period September 1994 through September 1997. All sub-
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jects were offered transthoracic echocardiographic evalua-
tion soon after the announcement on September 15, 1997,
of the voluntary withdrawal of fenfluramine and dexfenflu-
ramine from the U.S. market (7). Specific attention was
given to any morphologic abnormalities of either right- or
left-sided heart valves, as well as the presence and extent of
valvular regurgitation.
METHODS
Weight-loss study. Participants in this echocardiographic
study were derived from a larger population of 591 subjects
participating in a four-year prospective, nonrandomized,
open-label study of combination therapy with phentermine
resin and dl-fenfluramine to promote and sustain weight
loss (8). All subjects were followed at the Center for the
Study of Nutrition Medicine. The study was approved by
the Institutional Review Board and granted investigational
new drug status by the FDA (IND no. 45,962).
Study subjects consisted of male and female volunteers
with body mass indexes .27 kg/m2 at baseline, age range 18
to 69 years old, baseline heart rate ,90 beats/min, and
blood pressure ,160/95 mm Hg. To meet entry criteria,
subjects must have had no prior adverse reactions to central
nervous system stimulants or other weight-loss agents, no
history of regular laxative use, no use of diet supplements or
investigational drugs within 30 days of baseline, and no
evidence of significant cardiac, immunologic, hepatic, renal,
pulmonary, hematologic, metabolic, neurologic or psychiat-
ric dysfunction. Women who were lactating, pregnant, or
planning to become pregnant were excluded. Subjects with
a positive drug screen for cocaine or a history of substance
abuse within the previous two years were also excluded.
All participants had a baseline medical and nutritional
history, physical examination, laboratory tests, and an elec-
trocardiogram (ECG). Nutritional medicine consultation,
dietary monitoring, and psychological screening were also
performed. All subjects were seen every two weeks for the
first two months and on a monthly basis thereafter. Partic-
ipants had more extensive clinical visits at 6, 12, 18, 24 and
30 months, which included a history, physical examination,
laboratory tests, and dietary questionnaire and consultation.
Because of the reported association of valvular heart
disease with phen-fen and the FDA recommendations, the
study was stopped prematurely, and drug therapy was
discontinued in all patients. Combination phen-fen use was
stopped after up to 30 months of drug therapy.
Medication schedule and dose changes. Dosing of phen-
fen started at one 15-mg capsule of phentermine resin and
one 20-mg tablet of dl-fenfluramine daily, and was titrated
up to 30 mg and 60 mg, respectively. This was done to
maximize appetite control and minimize side effects. The
period of active drug treatment lasted up to 30 months as an
adjuvant to diet, exercise, and behavior-modification pro-
grams.
Echocardiographic examination. The Beth Israel Dea-
coness Medical Center notified all study participants con-
cerning phen-fen with two separate registered letters and
offered them a free echocardiographic examination. Of the
original 591 participants, 226 subjects were self-referred for,
and underwent, echocardiographic evaluations within a
mean of 97 days from the manufacturer’s voluntary with-
drawal of fenfluramine and dexfenfluramine from the U.S.
market. All subjects continued to be followed after the drugs
were discontinued according to the protocol, which involved
routine clinic visits with a research nurse and physician and
follow-up telephone calls with patients or their personal
physicians. All subjects who did not return for an echocar-
diographic examination were doing well clinically, and they
either refused to have an echocardiogram or had one done
elsewhere.
Standard transthoracic two-dimensional echocardiogra-
phy, color flow mapping, and continuous wave and pulse
Doppler examinations were performed (Hewlett-Packard,
Model 2500 or 5500, Andover, Massachusetts). Images
were recorded on VHS tapes. All studies were reviewed and
evaluated by two independent and experienced echocardio-
graphers. The severity of a regurgitant lesion was assessed
on a qualitative scale of trace, mild, moderate, or severe,
using previously described methods (9,10). When tricuspid
regurgitation was present, pulmonary artery pressure was
estimated using the modified Bernoulli equation. Disagree-
ment between readers on the presence of trace versus mild
regurgitation occurred in four patients with aortic regurgi-
tation and seven patients with mitral regurgitation; there
was complete agreement on normal studies and moderate
regurgitation. Whenever a discrepancy existed between
readings, the more severe grading of valvular regurgitation
was used. Significant valvular disease was determined using
the FDA case definition—that is, mild or greater aortic
regurgitation or mitral regurgitation $ moderate. Results
were archived in the Beth Israel Deaconess Medical Center
Cor Cardiology Database.
Statistical analysis. Statistical analysis was done using a
commercially available statistical software program (SPSS,
Version 6, Chicago, Illinois). Demographic, clinical, and
echocardiographic characteristics of the subjects were com-
pared using independent two-sample t tests and chi-square
tests. Univariate analysis was used to identify differences in
clinical variables in patients with and without valvular
disease. Differences were considered statistically significant
at the p , 0.05 level.
Abbreviations and Acronyms
ECG 5 electrocardiogram
FDA 5 Food and Drug Administration
phen-fen 5 phentermine-fenfluramine
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RESULTS
The study population consisted of 183 women (81%) and 43
men (19%), with a mean age of 46.9 6 8.9 years and a mean
starting weight 110 6 25.2 kg (Table 1). All subjects had
normal baseline ECGs and glucose levels. The mean cho-
lesterol level was 215 6 37 mg/dl. At time of entry into the
study, 19 subjects said that they had a prior history of a
“heart murmur.” On our echocardiographic evaluation, only
2 of the 19 subjects had mild aortic regurgitation. Seven
subjects had type II diabetes and 43 had hypertension. No
significant differences in baseline characteristics except age
were found between those subjects undergoing echocardi-
ography and those who did not. The subjects with echocar-
diograms were slightly older.
Concomitant psychotropic and cardiac drug use was
present in 132 of 226 subjects. Twenty-seven subjects (20%)
were on serotonin reuptake inhibitors at some point during
the study. Five of 16 patients with significant valvular heart
disease (31%) took serotonin reuptake inhibitors, whereas
22 of the 116 without valvular heart disease (19%) used
them (p 5 NS). Other psychotropic drugs included tricyclic
antidepressants in 10 subjects and amphetamines in 2
subjects. Cardiac drug use, including diuretics, occurred in
26 subjects (20%). Four of 16 subjects with valvular heart
disease (25%) took cardiac medications; 22 of 116 subjects
without valvular heart disease (19%) used cardiac drugs (p 5
NS).
The most common side effect of phen-fen use at any time
during the study was a dry mouth, which occurred in 191
subjects (87%). Other common side effects included “not
feeling oneself” (83%), somnolence (61%), sleep disturbance
(60%), headache (59%) and confusion (51%).
Echocardiographic findings. Transthoracic echocardiog-
raphy was performed on our subjects, with close attention to
valve morphology and extent of valvular insufficiency (Table
2). In our study population of 226 subjects, only 18 subjects
(8%) had significant valvular regurgitation as defined by
FDA criteria. No subjects had severe regurgitation of any
valve. Of the 18 subjects with significant valve lesions, the
most common significant finding was mild or greater aortic
insufficiency in 15 subjects and 3 subjects with moderate
mitral regurgitation.
Of all the subjects with aortic regurgitation, 40 had only
trace aortic insufficiency, 12 had mild aortic insufficiency,
and only 3 subjects had moderate aortic insufficiency. In
terms of mitral regurgitation, 156 subjects (69%) had some
degree of mitral regurgitation, with most subjects (85%)
having only trace mitral regurgitation, 23 subjects having
mild and only 3 subjects with moderate mitral insufficiency.
Tricuspid valve regurgitation was seen in 141 subjects
(62%), with 93% of these subjects having only trace tricus-
pid regurgitation. Only two subjects had mild pulmonic
insufficiency. No patients had moderate or severe tricuspid
or pulmonic regurgitation.
Most subjects with valve disease in our study had regur-
gitation involving only a single heart valve. Six subjects (3%)
had involvement of both aortic and mitral valves, and two of
these subjects also had mild tricuspid regurgitation. Only
one patient (0.5%) had significant regurgitation of both
aortic and mitral valves by FDA criteria. Overall, aortic
valve disease represented the highest proportion of cases of
significant valvular regurgitation, followed by mitral, tricus-
pid and pulmonic, in declining order of prevalence.
For the purpose of analyzing the effect of phen-fen dose
on the prevalence of valvular regurgitation, we divided
subjects into low- and high-dose subgroups (Table 3).
Low-dose subjects were those taking ,3 tablets per day,
with phen-fen combinations of 1–1, 1–0, or 0–1 tablets.
High-dose groups were those taking $3 tablets, with
phen-fen combinations of 2–1, 1–2, 2–2, or 3–2 tablets.
Using FDA criteria for significant valvular regurgitation, no
significant differences were noted between groups when
separated by drug dose. We also analyzed the distribution of
valvular abnormalities by duration of medication. Again, no
significant differences were found between groups with





Age (yr) 46.9 6 8.9† 44.3 6 10
Start body mass
index (kg/m2)
39.8 6 7.7 40.3 6 9.1
Finish body mass
index (kg/m2)
35.9 6 7.2 36.8 6 8.7
Pulse (beats/min) 68 6 8 69 6 9
Blood pressure
(mm Hg)
120 6 14/75 6 14 122 6 15/77 6 10
Glucose (mg/dl) 94 6 27 97 6 38
Cholesterol (mg/dl) 215 6 37 213 6 46
HDL (mg/dl) 51.5 6 16 50.6 6 19
Triglycerides (mg/dl) 163 6 86 156 6 99
Diabetes mellitus 7 (3%) 19 (5%)
Hypertension 43 (19%) 88 (24%)
“Heart murmur” 19 (8%) 18 (4.9%)
Cigarette smoking
$1 ppd‡
4 (1.9%) 13 (3.5%)
Alcohol use
(.4 drinks/wk)
15 (6.9%) 36 (9.8%)
*Echo 5 echocardiographic evaluation; †mean value 6 SD; ‡ppd 5 packs per day.
Table 2. Valvular Regurgitation* (n 5 226)
Valves None Trace Mild Moderate
Aortic 171 (76%) 40 (18%) 12 (5%) 3 (1%)
Mitral 70 (31%) 130 (58%) 23 (10%) 3 (1%)
Tricuspid 85 (38%) 131 (58%) 10 (4%) 0
Pulmonic 178 (79%) 46 (20%) 2 (1%) 0
*No valve had severe regurgitation.
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valvular regurgitation when differentiated by duration of
drug therapy.
Univariate comparisons were performed for multiple
baseline variables between those subjects with significant
valvular heart disease (n 5 18) and those without valvular
disease (n 5 208). The variables analyzed and their matched
values in both groups are shown in Table 4. No significant
differences were found between those with and without
valvular heart disease when compared by phentermine or
fenfluramine dose, age, start/finish weights, percentage
weight loss, body mass index, baseline mean heart rate,
blood pressure, fasting cholesterol or serum glucose mea-
surements.
DISCUSSION
Our echocardiographic investigation involved subjects tak-
ing phen-fen combination therapy within the guidelines of
a strict, medically supervised study protocol, with a single
central echocardiographic reading center, and extensive data
collection regarding numerous potential confounding vari-
ables. Early reports describing the prevalence of valvular
heart disease associated with phen-fen in less well-defined
study populations have found significant valvular pathology
in up to 38% of cases (3); this is much higher than
previously reported Doppler studies of randomly derived
samples from the general population (11,12). In our study
population, only 18 subjects (8%) had significant valvular
regurgitation of the aortic or mitral valves by FDA criteria.
These findings question the contribution of phen-fen ther-
apy as an independent risk factor for valvular regurgitation.
Valvular regurgitation in normal subjects. Singh and
colleagues (12) have recently reported their retrospective
analysis of valvular regurgitation in a population-based
cohort of subjects from the Framingham Heart Study
(Table 5). This represents the closest control population to
our group, and is derived from a similar geographic area. A
total of 1,663 men (age 55 6 10 years) and 1,966 women
(age 54 6 10 years) underwent routine two-dimensional
and color flow echocardiography with close attention to
valvular regurgitation. In their cohort, 1.6% of subjects had
moderate or greater mitral regurgitation, whereas 4.8% had
mild or greater aortic insufficiency. In our population, 1.3%
of subjects had moderate or greater mitral regurgitation and
6.6% had mild or greater aortic insufficiency, which is
similar to the Framingham population sample. Thus, it
appears that a significant proportion of healthy men and
women have detectable valvular regurgitation by color flow
Doppler, and that valvular abnormalities may represent
age-related degenerative changes. In addition, the FDA’s
criteria for aortic regurgitation may be too narrow, and the
case definition for pathologic regurgitation may need to be
modified or made age specific.



































*Low dose: Fewer than 3 tablets (phen-fen combinations of 1-1, 0-1, 1-0).
High dose: Equal to or greater than 3 tablets (2-1, 1-2, 2-2, 3-2).








Fen dose (mg) 29.4 6 10.3 27.2 6 10.9 0.43
Phen dose (mg) 17.6 6 5.9 17.7 6 6.0 0.96
Mean duration
(months)
12.9 6 8.6 12.3 6 7.3 0.76
Age (yrs) 48.3 6 10.9 46.9 6 8.9 0.54
Start weight (kg) 108.2 6 28.6 110.4 6 24.9 0.73
Finish weight (kg) 96.3 6 22.4 99.8 6 23.8 0.56
% Weight loss 10.2 6 7.0 9.5 6 6.9 0.69
BMI† (kg/m2) 40.1 6 8.7 39.6 6 7.6 0.77
Mean heart rate 69.0 6 8.2 68.0 6 8.5 0.62
SBP‡ (mm Hg) 122.9 6 15.9 120.1 6 14.8 0.45
DBP§ (mm Hg) 78.5 6 10.7 75.5 6 10.2 0.25
*VHD 5 valvular heart disease (by FDA criteria); †BMI 5 body mass index; ‡SBP 5
systolic blood pressure; §DBP 5 diastolic blood pressure; data are mean value 6 SD.
Table 5. Prevalence of Valvular Heart Disease in the
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Valvular disease with phen-fen. In September 1997, the
FDA received independent echocardiographic prevalence
surveys of patients from five different areas who had received
dexfenfluramine or fenfluramine alone or in combination
with phentermine (3). Most subjects (87%) were women,
with sample sizes ranging from 20 to 115 patients (total
patients 5 284), with a mean age of 48 years (range 46 to 51
years), and median duration of drug exposure of 14 months
(range 6 to 30 months). The median dose of fenfluramine
was 40 mg/day (20 to 60 mg/day), phentermine 30 mg/day
(15 to 37.5 mg/day) and dexfenfluramine 30 mg/day (15 to
30 mg/day). Although the methodology of these surveys
differed, the prevalence of valvular disease meeting the FDA
case definition for significant valvular regurgitation was
similar in all five surveys, and ranged from 30.0% to 38.3%
(overall: 32.8%). The prevalence of valvular abnormalities
was increased with drug use $6 months. However, our data
in a similar age population showed a significantly lower
prevalence of valvular heart disease and no relationship to
dose or duration of phen-fen use.
A recent report from Khan et al. (13) described the effects
of three appetite-suppressant drugs in a modified study,
which included echocardiography to evaluate the presence
of valve disease in patients after they stopped taking the
drugs. Using FDA criteria, valve regurgitation was present
in 25.2% of patients (n 5 163) taking phen-fen, 12.8% of
patients (n 5 39) given dexfenfluramine, and 22.6% of
patients (n 5 31) taking dexfenfluramine and phentermine.
Their results may differ from our investigation owing to the
much higher dose and duration of drug therapy. In addition,
echocardiography was performed much earlier in their
study, with 18% of patients taking drugs at the time of the
echocardiogram, and another 20% within 30 days of stop-
ping medications.
Another recent investigation by Weissman et al. (14)
evaluated the use of dexfenfluramine on valvular heart
disease. Their study compared echocardiograms of 1,072
patients taking dexfenfluramine hydrochloride, sustained-
release dexfenfluramine or placebo. Using the FDA case
definition, significant aortic regurgitation was seen in only
5% of dexfenfluramine patients, 5.8% of patients on
sustained-release dexfenfluramine, and 3.6% on placebo;
significant mitral regurgitation occurred in 1.7%, 1.8%, and
1.2% of patients, respectively. Overall, no statistically sig-
nificant increase occurred in the prevalence of clinically
relevant heart valve regurgitation following dexfenfluramine
use for up to three months compared with placebo. These
findings are consistent with our own results, as well as those
of the Framingham Heart Study, and they suggest that the
short-term use of dexfenfluramine is not associated with a
significant increased risk for valve disease.
The anorectic action of fenfluramine may be mediated
through the activation of serotonergic pathways in the brain;
phentermine is a noradrenergic agent, which interferes with
the pulmonary clearance of serotonin. Histopathologic
changes noted in prior studies of patients on phen-fen are
characterized by fibroplasia involving the valvular endocar-
dium, which are microscopically identical to those seen in
patients with ergot-alkaloid–induced and carcinoid valve
disease (2,4–6). Twenty percent of our subjects were taking
serotonin reuptake inhibitors, yet there was no increased
prevalence of valvular heart disease in those taking serotonin
reuptake inhibitors compared with those not taking these
drugs.
Study limitations. Although all subjects were followed in a
prospective, carefully controlled investigational protocol and
multiple readers at one center interpreted all echocardio-
grams, there are limitations to our study. First, our study did
not have a control group and not all subjects had an
echocardiographic evaluation. However, the prevalence of
valvular disease in our study was similar to the prevalence in
the Framingham Heart Study. In addition, no significant
differences in baseline characteristics were found between
those subjects with and without echocardiographic exami-
nations, and all subjects currently are asymptomatic and
doing well clinically.
Second, inherent inaccuracies exist in differentiating rel-
atively mild degrees of valvular regurgitation, especially
using qualitative scoring systems; our study is no different
from previous reports in this regard. The differentiation of
trace from mild degrees of valvular regurgitation is subjec-
tive, and both intra- and interobserver variations are to be
expected. We accounted for this by using multiple readers,
and we recorded the largest degree of valvular regurgitation
for the purpose of data analysis.
Third, in a study population such as ours and the
Framingham Heart Study, most valve lesions occurred in
asymptomatic individuals without a history of heart mur-
murs. Prior random population surveys have shown that
only 17% of all patients with echocardiographic evidence of
valvular heart disease have audible heart murmurs (3). Given
that historical and physical examinations do not appear
sensitive enough to assess the true prevalence of valvular
lesions in such a population, and that few subjects had
pretreatment echocardiograms for comparison, selection
bias could play a significant role in the final analysis of any
given population.
Fourth, neither direct inspection nor histopathologic
confirmation was performed in any patient. Therefore, our
study does not address the issue of whether or not histologic
changes secondary to phen-fen use (which were not visible
macroscopically by transthoracic echocardiography) may
still have occurred. Finally, our study did not address the
development of significant valvular disease in the future.
Long-term, prospective studies will be needed to answer
that question.
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